Expression of tumor antigens on primary ovarian cancer cells compared to established ovarian cancer cell lines

Kamila Kloudová; Hana Hromádková; Simona Partlová; Tomáš Brtnický; Lukáš Rob; Jiřina Bartůňková; Michal Hensler; Michael J. Halaška; Radek Špíšek; Anna Fialová

doi:10.18632/oncotarget.10028

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Expression of tumor antigens on primary ovarian cancer cells compared to established ovarian cancer cell lines

Kamila Kloudová, Hana Hromádková, Simona Partlová, Tomáš Brtnický, Lukáš Rob, Jiřina Bartůňková, Michal Hensler, Michael J. Halaška, Radek Špíšek and Anna Fialová _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:46120-46126. https://doi.org/10.18632/oncotarget.10028

Metrics: PDF 3233 views | HTML 3970 views | ?

Abstract

Kamila Kloudová1,3, Hana Hromádková1, Simona Partlová1,3, Tomáš Brtnický2, Lukáš Rob2, Jiřina Bartůňková1, Michal Hensler3, Michael J. Halaška2, Radek Špíšek1,3, Anna Fialová1,3

1Department of Immunology, Charles University, 2nd Faculty of Medicine, University Hospital Motol, Prague, Czech Republic

2Department of Obstetrics and Gynaecology, Charles University, 2nd Faculty of Medicine, University Hospital Motol, Prague, Czech Republic

3Research Department, Sotio, Prague, Czech Republic

Correspondence to:

Anna Fialová, email: [email protected]

Keywords: high-grade serous epithelial ovarian cancer, tumor-associated antigens, immunotherapy, cancer cell lines

Received: January 13, 2016 Accepted: May 26, 2016 Published: June 14, 2016

ABSTRACT

In order to select a suitable combination of cancer cell lines as an appropriate source of antigens for dendritic cell-based immunotherapy of ovarian cancer, we analyzed the expression level of 21 tumor associated antigens (BIRC5, CA125, CEA, DDX43, EPCAM, FOLR1, Her-2/neu, MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A10, MAGE-A12, MUC-1, NY-ESO-1, PRAME, p53, TPBG, TRT, WT1) in 4 established ovarian cancer cell lines and in primary tumor cells isolated from the high-grade serous epithelial ovarian cancer tissue. More than 90% of tumor samples expressed very high levels of CA125, FOLR1, EPCAM and MUC-1 and elevated levels of Her-2/neu, similarly to OVCAR-3 cell line. The combination of OV-90 and OVCAR-3 cell lines showed the highest overlap with patients’ samples in the TAA expression profile.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 10028

Publication Alerts

Research Papers:

Expression of tumor antigens on primary ovarian cancer cells compared to established ovarian cancer cell lines

Abstract